Henry Schein's (HSIC) dental software business, Henry Schein One, has introduced two new tools — Eligibility Essentials and Eligibility Pro — to simplify the insurance eligibility process for dental practices. Currently available for Dentrix and Dentrix Ascend cloud-based practice management solutions, the new tools are designed to help foster trust between dental practices and patients by reducing insurance-related surprises. Henry Schein One is the largest component in the company's Technology and value-a ...

Group 1 - Henry Schein shares have increased by approximately 5.6% over the past month, underperforming the S&P 500 [1] - Merit Medical reported revenues of $338 million for the last quarter, reflecting a year-over-year growth of 5.6% [2] - Earnings per share (EPS) for Merit Medical in the last quarter was $0.92, compared to $0.81 a year ago [2] Group 2 - Merit Medical is projected to report earnings of $0.80 per share for the current quarter, indicating a year-over-year increase of 6.7% [3] - The Zacks Consensus Estimate for Merit Medical has changed by +0.2% over the last 30 days [3] - Merit Medical holds a Zacks Rank of 3 (Hold) based on the overall direction and magnitude of estimate revisions [3]

Henry Schein (HSIC) reported $3.14 billion in revenue for the quarter ended June 2024, representing a yearover-year increase of 1.2%. EPS of $1.23 for the same period compares to $1.31 a year ago. The reported revenue represents a surprise of -4.33% over the Zacks Consensus Estimate of $3.28 billion. With the consensus EPS estimate being $1.22, the EPS surprise was +0.82%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ...

Henry Schein, Inc. (HSIC) registered adjusted earnings per share (EPS) of $1.23 in the second quarter of 2024, down 6.1% from the year-ago period's adjusted EPS. However, the metric exceeded the Zacks Consensus Estimate by 0.8%. Revenues in Detail Henry Schein reported net sales of $3.14 billion in the second quarter, up 1.2% year over year. The metric lagged the Zacks Consensus Estimate by 4.3%. The year-over-year upside reflects an internal sales decline of 2.4%. On a geographic basis, the company recorde ...

Henry Schein (HSIC) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $1.31 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 0.82%. A quarter ago, it was expected that this health care products maker would post earnings of $0.99 per share when it actually produced earnings of $1.10, delivering a surprise of 11.11%. Over the last four quart ...

Henry Schein (HSIC) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on August 6, 2024, might help the stock move higher if these key numbers are better than exp ...

Hims & Hers Health's earnings are expected to surge 281.8% in 2024 compared with the industry's 15.7% growth. HIMS' earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. Its shares have surged 131% against the industry's 27.1% decline in the past year. HIMS sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. Haemonetics, sporting a Zacks Rank #1 at present, has an estimat ...

Market Overview - The current market behavior resembles the late 1990s, characterized by significant gains in a limited number of companies, leading to concerns about market concentration [1][4][3] - The "Magnificent Seven" have been pivotal in driving the S&P 500's overall gains, with market concentration reaching its highest level in at least 50 years [4][3] MarketAxess (MKTX) - MarketAxess has seen revenue growth from $511 million in 2019 to an estimated $814 million in 2023, with an 8% revenue growth this year [2] - Analysts anticipate a return to double-digit growth in both top and bottom lines by 2025 [2] - Despite a significant decline in stock value since its 2020 peak, the credit market's size supports both MarketAxess and its competitor Tradeweb, with potential for increased trading activity once interest rates are cut [8][7] Henry Schein (HSIC) - Henry Schein is the largest provider of dental equipment globally, operating in 33 countries and serving over one million customers [10] - The dental market is expected to grow rapidly due to increased consumer focus on aesthetics and an aging population, leading to higher demand for dental services [11][12] - Since its IPO in 1995, Henry Schein has achieved an 11.5% compounded annual growth rate in revenues, with strong growth prospects ahead [13] McCormick (MKC) - McCormick dominates the U.S. spices and seasonings market, controlling an estimated 40% to 60% market share in its primary categories [15] - The company has shown remarkable stock performance, with shares rising over 6,500% in the past 40 years, benefiting from strong consumer demand for flavorful foods [16] - McCormick is expanding into adjacent markets through acquisitions, such as Frank's and Cholula, to enhance its position in the hot sauce category [17]

Company Overview - Henry Schein Inc. (HSIC) is well positioned due to its extensive global presence and diverse distribution channels, although macroeconomic concerns are negatively impacting its operational results [1][5] - The company has strategically established distribution centers worldwide, enhancing customer service and operational efficiency, with a presence in North America, Australia, New Zealand, and emerging markets like China, Brazil, Israel, the Czech Republic, and Poland [2] Business Segments - In the Dental business, Henry Schein focuses on delivering customized solutions by leveraging market insights and technological advancements, while also selling cost-effective consumable products and manufacturing dental specialty products [3] - The company is optimistic about its dental technology joint venture, Henry Schein One, which is driving significant gains in core products such as practice management software and AI solutions [4] Financial Performance - The current macroeconomic environment, including exchange rate fluctuations, inflation, and recession, is adversely affecting Henry Schein's financial operations, leading to a 10.3% increase in selling, general, and administrative expenses in the first quarter compared to the previous year [5] - In the first quarter of 2024, the company's Technology and Value-Added service sales grew by 13.8% year-over-year, with North American growth driven by value-added services and international growth led by dental cloud-based solutions [10] Market Position - Henry Schein is experiencing consistent demand for its implant systems, endodontic products, and integrated software solutions, and is gaining market share in the Global Dental specialties market through acquisitions [11] - However, the company faced a decline in fourth-quarter 2023 sales by an estimated $350 million-$400 million due to a cybersecurity incident, which also impacted operating income by approximately $120 million-$130 million [12]

What are the Zacks Style Scores? Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. It also includes access to the Zacks Style Scores. The Zac ...